{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:51:33Z","timestamp":1779234693123,"version":"3.51.4"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and aim<\/jats:title><jats:p>Molecular mechanism of translocation and outcome in variant chronic myeloid leukaemia (vCML) has been a topic of debate. While several cytogenetic studies suggest a low response to Imatinib Mesylate, others demonstrate a similar disease course in both classical and vCML. Besides, many studies comprehensively also link tyrosine kinase domain (TKD) mutations with aggressive clinical outcome. Thus, we aim to study the molecular mechanism of translocation, identify the third partner chromosomes and comment on the disease course and clinical outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We cytogenetically characterised 25 vCML cases to determine the third partner chromosome, mechanism of translocation and prognostic outcome. We also compared vCML cases with and without TKD mutation to most appropriately outline the clinical consequence and ascertain the potent cause of unresponsiveness to treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Third partner chromosome in variant translocation was defined by conventional and molecular cytogenetics. Although in our study most cases showed inadequate clinical response attributable to TKD mutation rather than variant translocation, we observed an inferior outcome in cases involving chromosome 5 as the third partner.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Thus, we conclude that characterising and reporting new cases of variant translocations, involving various different chromosomes as third partner (with different breakpoints) by cytogenetics, will lead to a better understanding of the disease. To the best of our knowledge, this kind of delineate study has not been applied to precisely comment on the prospects of cytogenetically characterised vCML.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13522","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T10:45:36Z","timestamp":1614249936000},"page":"99-108","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of cytogenetic response in CML patients with variant Philadelphia translocation"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-3176","authenticated-orcid":false,"given":"Dhanlaxmi","family":"Shetty","sequence":"first","affiliation":[{"name":"Department of Cancer Cytogenetics Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre  Kharghar Navi Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Talker","sequence":"additional","affiliation":[{"name":"Department of Cancer Cytogenetics Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre  Kharghar Navi Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemani","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Cancer Cytogenetics Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre  Kharghar Navi Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Talker","sequence":"additional","affiliation":[{"name":"Department of Cancer Cytogenetics Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre  Kharghar Navi Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Patkar","sequence":"additional","affiliation":[{"name":"Hematopathology Laboratory Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre  Kharghar Navi Mumbai India"},{"name":"Homi Bhabha National Institute (HBNI)  Anushaktinagar Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Papagudi","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Hematopathology Laboratory Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre  Kharghar Navi Mumbai India"},{"name":"Homi Bhabha National Institute (HBNI)  Anushaktinagar Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasmukh","family":"Jain","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute (HBNI)  Anushaktinagar Mumbai India"},{"name":"Medical Oncology Department Tata Memorial Hospital, Tata Memorial Centre  Parel Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avinash","family":"Bonda","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute (HBNI)  Anushaktinagar Mumbai India"},{"name":"Medical Oncology Department Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre  Kharghar Navi Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Punatar","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute (HBNI)  Anushaktinagar Mumbai India"},{"name":"Medical Oncology Department Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre  Kharghar Navi Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anant","family":"Gokarn","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute (HBNI)  Anushaktinagar Mumbai India"},{"name":"Medical Oncology Department Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre  Kharghar Navi Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute (HBNI)  Anushaktinagar Mumbai India"},{"name":"Medical Oncology Department Tata Memorial Hospital, Tata Memorial Centre  Parel Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manju","family":"Sengar","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute (HBNI)  Anushaktinagar Mumbai India"},{"name":"Medical Oncology Department Tata Memorial Hospital, Tata Memorial Centre  Parel Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navin","family":"Khattry","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute (HBNI)  Anushaktinagar Mumbai India"},{"name":"Medical Oncology Department Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre  Kharghar Navi Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_8_3_1","first-page":"1333","article-title":"Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance","volume":"9","author":"Marcucci G","year":"2003","journal-title":"Clinic Cancer Res."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24536"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.138036"},{"issue":"4","key":"e_1_2_8_6_1","first-page":"1","article-title":"Chronic myeloid leukemia with variant chromosomal translocations: results of treatment with Imatinib mesylate","volume":"11","author":"Bhise R","year":"2012","journal-title":"Online J Health Allied Scs."},{"key":"e_1_2_8_7_1","first-page":"5705","article-title":"Conventional and molecular cytogenetic studies to characterize 32 complex variant Philadelphia translocations in patients with chronic myeloid leukemia","volume":"17","author":"Costa D","year":"2019","journal-title":"Oncol letters."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/isbn.978-3-318-05979-3"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2896"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328294"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20196"},{"issue":"2","key":"e_1_2_8_13_1","first-page":"61","article-title":"Clinical implications of simultaneous occurrence of variant Philadelphia translocations in chronic myeloid leukemia","volume":"45","author":"Trivedi P","year":"2019","journal-title":"J Assoc Genet Technol."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.2015.0237"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(96)00168-9"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1598-8"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/187125"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04899.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04291.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/gtmb.2012.0147"},{"issue":"2","key":"e_1_2_8_21_1","first-page":"724","article-title":"BCR\u2010ABL del.C.1086\u20101270 (p.r362fs*21) and TKI resistance in CML patients from Russian federation","volume":"102","author":"Abdullaev A","year":"2017","journal-title":"Eur Hematol Asso."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/02841861003660031"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13522","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13522","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T15:31:19Z","timestamp":1693236679000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1111\/ajco.13522"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13522","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"assertion":[{"value":"2020-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}